ESiOR Oy participates in the 4th Nordic Conference on Research in Patient Safety and Quality in Healthcare 19th-20th May 2016 in Hotel Puijonsarvi, Kuopio. We will be
Most health economists have probably faced a situation where ICER, CEEF, CEAF, EVPI or some other complicated cost-utility analysis outcome do not alone make the
ESiOR had the privilege to participate in the excellent working group meeting “Management, steering and surveillance by knowledge” organised by the Finnish Ministry of Social
ESiOR participated actively in Utilization of SOTE (social welfare and health care) information seminar , which took place 27th January 2016 in Helsinki, Finland. CEO Erkki Soini
The publication promotes some of the key expertise and opportunities that Kuopio offers for developing companies as well as presents the local health and wellbeing
Single-bed hospital rooms are associated with significant benefits based on earlier research. However, the initial investment per bed in single-bed rooms exceeds the initial investment
”The National Institute for Health and Welfare (THL) has granted this year’s public health award to HK Ruokatalo for the nationally significant promotion of public
In our recent publication, we analysed the cost-effectiveness of dabigatran in the prevention of stroke for patients with atrial fibrillation. The published analyses are based
Our recent publication assessed the real-life use of extended and immediate release quetiapine in patients with schizophrenia spectrum disorders and bipolar disorder in Lappeenranta. Much
Janne Martikainen, PhD (health economist and partner of ESiOR Ltd) is the first adjunct professor in the economic evaluation of pharmaceuticals in Finland.
We analysed the impact of pharmaceutical pricing scheme on cost-effectiveness analyses in Finland. The Finnish drug retail prices are based on computational pricing scheme that
ESiOR provides health-economic information in a form that supports decision-making. We design studies to evaluate, address and communicate the profitability and value associated with investment
